Agenus Inc. (AGEN) Reports 51% Survived 18 Months on BOT+BAL

Agenus Inc. reported that 51% of 123 patients with a specific type of colorectal cancer survived at least 18 months on its BOT+BAL treatment, with an estimated 59% of those alive at three years. This is a post-hoc analysis of prior Phase 1b results, not a new trial.

Original reporting
Published Nov 6, 2026, 2:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 2:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Agenus Inc. (AGEN) Reports 51% Survived 18 Months on BOT+BAL — source image
Decision brief

The 30-second read

$AGENBullishLow
01

Why it matters

It provides additional survival durability statistics (18-month and estimated 3-year survival among responders), but the lack of a new controlled trial readout limits how much it can change near-term expectations.

02

Market read

Supportive but non-prospective survival durability data may modestly bolster sentiment, yet it is unlikely to drive a major repricing without prospective Phase 3 results.

03

What to watch

Traders may discount the signal until the company’s prospective Phase 3 ROBBIN strategy reports, and may also weigh the lack of active liver metastases as a selection effect.

Relevance 4/10Novelty 4/10Timing: today’s post-hoc update on previously reported Phase 1b results

Background

The piece is a post-hoc analysis of previously reported Phase 1b results for BOT+BAL in refractory MSS metastatic colorectal cancer without active liver metastases.

Company-level read

Ticker impact

$AGENBullishMedium confidence
Context

Agenus reports a post-hoc analysis where 51% of 123 refractory MSS metastatic colorectal cancer patients survived at least 18 months on BOT+BAL.

Expected impact

Likely limited near-term upside as traders may view the results as supportive yet non-prospective, reducing conviction versus prospective Phase 3 evidence.

Evidence & confidence

The article provides additional survival percentages but states it is post-hoc of previously reported Phase 1b results, implying lower incremental decision value than a new trial endpoint or regulatory milestone.

Market effects

Adds incremental sentiment for immuno-oncology/biotech trial durability narratives, but without prospective Phase 3 confirmation it is unlikely to re-rate the broader sector materially.

No clear regional market linkage beyond US biotech sentiment.

Limited global relevance since the update is a company-specific post-hoc analysis rather than a cross-market regulatory or approval event.

Counterpoint

Because the analysis is post-hoc and limited to patients without active liver metastases, the survival durability may not generalize and could be overstated versus prospective endpoints.

Key entities

  • Agenus Inc.

    Subject of the article, reporting post-hoc survival outcomes for BOT+BAL in a defined MSS colorectal cancer subgroup.

  • BOT+BAL

    Treatment regimen evaluated in the Phase 1b dataset underlying the post-hoc analysis.

  • ROBBIN strategy

    Prospective Phase 3 strategy referenced as the larger catalyst needed for stronger read-through.

Related articles

$AGENMedAI 8/10

Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study

AGENUS INC (AGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study • ROBBIN Phase 3 on track for first patient enrolled in Q1 2027; strong global investigator engageme

$AGENMedAI 8/10

Agenus advances Phase 3 colon cancer trial, posts Q3 profit

Agenus Inc. (AGEN) reported Q3 revenue of $31.5M, up from $30.2M YoY, with net income of $2.8M. The company announced plans to enroll the first patient in its Phase 3 ROBBIN trial for colon cancer in Q1 2027, with interim results expected in Q4 2027. Two Phase 2 studies showed 30% pathologic complete response rates. Armenia granted marketing authorization for botensilimab and balstilimab. AGEN has $86.9M in cash and raised $85M in a private placement.